trans-N-(3H-1,2,3-triazolo[4,5-d]-pyrimidin-7-yl)-4-aminomethylcyclohexanecarboxamide | 752955-85-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: trans-N-(3H-1,2,3-triazolo[4,5-d]-pyrimidin-7-yl)-4-aminomethylcyclohexanecarboxamide
• CAS: 752955-85-4
• 化学式: C₁₂H₁₇N₇O
• 分子量: 275.313
• InChiKey: NTYZGJYQFIWUPS-ZKCHVHJHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.45
• 重原子数：
  20.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  122.47
• 氢给体数：
  3.0
• 氢受体数：
  6.0

文献信息

• Preventives/remedies for kidney diseases
  申请人：——

  公开号：US20030096843A1

  公开（公告）日：2003-05-22

  A compound having a Rho kinase inhibitory activity, such as (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)-cyclohexane, has a renal interstitial fibrosis inhibitory action in renal interstitial fibrosis model mice and various other actions, and therefore, is useful as an agent for the prophylaxis or treatment of renal diseases.

  具有Rho激酶抑制活性的化合物，例如（+）-trans-4-(1-氨乙基)-1-(4-吡啶基氨甲酰基)-环己烷，对于肾间质纤维化模型小鼠具有肾间质纤维化抑制作用和其他各种作用，因此，可用作预防或治疗肾脏疾病的药物。
• Agent for prophylaxis and treatment of glaucoma
  申请人：——

  公开号：US20030125351A1

  公开（公告）日：2003-07-03

  An agent for the prophylaxis and treatment of glaucoma, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of glaucoma, which contains a compound of the formula (I) 1 wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided. The agent for the prophylaxis and treatment of glaucoma of the present invention is a novel agent for the prophylaxis and treatment of glaucoma and has intraocular pressure lowering action, optic disc blood flow improving action and aqueous humor outflow promoting action.

  一种预防和治疗青光眼的药剂，其中包含一种具有Rho激酶抑制活性的化合物，特别是一种预防和治疗青光眼的药剂，其中包含式（I）1的化合物，其中每个符号如规范中所定义，作为具有Rho激酶抑制活性的化合物。本发明的预防和治疗青光眼的药剂是一种新型的预防和治疗青光眼的药剂，具有降低眼内压、改善视盘血流和促进房水排出的作用。
• Antitumor effect potentiators
  申请人：——

  公开号：US20030165576A1

  公开（公告）日：2003-09-04

  When used concurrently with an antitumor agent, a compound having a Rho kinase inhibitory activity, such as (R)-(+)-N-(4-pyridyl)-4-(1-aminoethyl)benzamide, reinforces an antitumor effect of the antitumor agent and is useful as an antitumor effect potentiator. Particularly, a compound having a Rho kinase inhibitory activity used with an antitumor agent in combination can reduce the dose of the antitumor agent, which in turn affords provision of a sufficient effect and/or reduction of side effects.

  当与抗肿瘤药物同时使用时，具有Rho激酶抑制活性的化合物，如(R)-(+)-N-(4-吡啶基)-4-(1-氨乙基)苯甲酰胺，可以增强抗肿瘤药物的抗肿瘤效果，并且可用作抗肿瘤效应增强剂。特别是，与抗肿瘤药物联合使用具有Rho激酶抑制活性的化合物可以降低抗肿瘤药物的剂量，从而提供足够的疗效和/或减少副作用。
• Substituted azabicyclic compounds
  申请人：——

  公开号：US20020173527A1

  公开（公告）日：2002-11-21

  This invention is directed to physiologically active compounds of formula (I) 1 wherein 2 represents a bicyclic ring, system, of 9 ring members, in which the ring 3 is an oxazole, and the ring 4 is a benzene ring; R 1 represents hydrogen or a straight- or branched-chain alkyl group of 1 to about 4 carbon atoms, optionally substituted by hydroxy or one or more halogen atoms, or when Z 1 represents a direct bond R 1 may also represent a lower alkenyl or lower alkynyl group, or a formyl group; R 2 represents hydrogen, alkenyl, alkoxy, alkyl, alkylsulphinyl, alkylsulphonyl, alkylthio, aryl, arylalkyloxy, arylalkylsulphinyl, arylalkylsulphonyl, arylalkylthio, aryloxy, arylsulphinyl, arylsulphonyl, arylthio, cyano, cycloalkenyl, cycloalkenyloxy, cycloalkyl, cycloalkyloxy, hydroxy, —SO 2 NR 4 R 5 , —NR 4 SO 2 R 5 , —NR 4 R 5 , —C(═O)R 5 , —C(═O)C(═O)R 5 , —C(═O)NR 4 R 5 , —C(═O)OR 5 , —O(C═O)NR 4 R 5 , or —NR 4 C(═O)R 5 ; R 3 represents —C(═Z)—N(R 7 )R 6 ; A 1 represents a straight or branched C 1-6 alkylene chain optionally substituted by hydroxyl, alkoxy, oxo, cycloalkyl, aryl or heteroaryl; Z 1 represents a direct bond, an oxygen or sulphur atom or NH; n is zero; and mis 1; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.

  本发明涉及公式（I）的生理活性化合物，其中2表示一个由9个环成的双环环系统，在该环3中为噁唑环，环4为苯环; R1表示氢或1至约4个碳原子的直链或支链烷基，可选地被羟基或一个或多个卤素原子取代，或当Z1表示直接键时，R1也可以表示低烯基或低炔基或甲酰基; R2表示氢、烯基、烷氧基、烷基、烷基磺酰基、烷基磺酰基、烷基硫基、芳基、芳基烷氧基、芳基烷基磺酰基、芳基烷基磺酰基、芳基烷基硫基、芳氧基、芳基磺酰基、芳基磺酰基、芳基硫基、氰基、环烯基、环烯基氧基、环烷基、环烷基氧基、羟基、-SO2NR4R5、-NR4SO2R5、-NR4R5、-C(═O)R5、-C(═O)C(═O)R5、-C(═O)NR4R5、-C(═O)OR5、-O(C═O)NR4R5或-NR4C(═O)R5; R3表示-C(═Z)-N(R7)R6; A1表示一条直链或支链C1-6烷基链，可选地被羟基、烷氧基、氧代、环烷基、芳基或杂环芳基取代; Z1表示直接键、氧原子或硫原子或NH; n为零; m为1;及其N-氧化物，以及公式（I）化合物和其N-氧化物的前药体，以及它们的制药可接受的盐和溶剂。这些化合物抑制TNF的产生或生理效应，并抑制环磷酸腺苷磷酸二酯酶。本发明还涉及包括公式（I）化合物的制药组合物，其制药用途和制备方法。
• Visual function disorder improving agents
  申请人：——

  公开号：US20040106646A1

  公开（公告）日：2004-06-03

  The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-( 1 H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent has axon of the retinal ganglion cellal extension promoting action and optic nerve cell regeneration promoting action, and is useful for the treatment of a visual function disorder associated with various eye diseases caused by damage, defects, degeneration and the like in the retinal or optic nerve.

  本发明提供了一种含有具有Rho激酶抑制活性的化合物的视觉功能障碍改善剂，特别是(R)-(+)-N-(1H-吡咯[2,3-b]吡啶-4-基)-4-(1-氨基乙基)苯甲酰胺作为有效成分。该剂具有促进视网膜神经节细胞轴突延伸和视神经细胞再生的作用，可用于治疗与视网膜或视神经的损伤、缺陷、退化等引起的各种眼部疾病相关的视觉功能障碍。